Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids

J Neuroimmunol. 2011 Jul;236(1-2):111-7. doi: 10.1016/j.jneuroim.2011.05.005. Epub 2011 Jun 8.

Abstract

Interferon-β (IFN-β) is known to expand regulatory CD56(bright) natural killer (NK) cells in multiple sclerosis (MS). In this cross-sectional study we show that MS patients treated with IFN-β alone or in combination with low-dose prednisolone displayed increased proportion of all NK cell subsets in the active phase of the cell cycle (Ki-67+). There was no difference in NK cell apoptosis markers. In vitro experiments showed that both IFN-β and IFN-β in combination with corticosteroids increased the proportion of Ki-67(+) NK cells. This study, although limited, shows that treatment with IFN-β affects NK cell cycle without altering NK cell apoptosis in MS patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Cells, Cultured
  • Cohort Studies
  • Cross-Sectional Studies
  • Drug Therapy, Combination
  • Humans
  • Interferon-beta / administration & dosage*
  • Ki-67 Antigen / biosynthesis*
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / metabolism*
  • Killer Cells, Natural / pathology*
  • Lymphocyte Count
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / pathology*
  • Prednisolone / administration & dosage*

Substances

  • Ki-67 Antigen
  • Interferon-beta
  • Prednisolone